Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: Similarities and differences in the mechanisms of action

Immunology

Volumn 121, Issue 2, 2007, Pages 248-257

  Sharabi, Amir ^a   Azulai, Hava ^b   Sthoeger, Zev M ^b   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN HOSPITAL   (Israel)

Author keywords

Apoptosis; Cyclophosphamide; Cytotoxic T lymphocyte antigen 4; Immunoregulatory T cells; Modulating peptide

Indexed keywords

AUTOANTIBODY; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CD28 ANTIGEN; CD45RB ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA ANTIBODY; EDRATIDE; GAMMA INTERFERON; GLYCYLTYROSYLTYROSYLTRYPTOPHYLSERYLTRYPTOPHYLISOLEUCYLARGINYL GLUTAMINYLPROLYLPROLYLGLYCYLLYSYLGLYCYLGLUTAMYLGLUTAMYLTRYPTOPHYLISOLEUCYL GLYCINE; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; MONOTHERAPY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SEROLOGY; SPLEEN; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UPREGULATION;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CD4-POSITIVE T-LYMPHOCYTES; COMPLEMENTARITY DETERMINING REGIONS; CYCLOPHOSPHAMIDE; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NZB; PEPTIDE FRAGMENTS; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 34247485287     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02565.x     Document Type: Article

References (25)

1. Mok CC, Wong RWS, Lai KN. Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 2003 62 : 799 804.
2. Waisman A, Ruiz PJ, Israeli E, Eilat E, Konen-Waisman S, Zinger H, Dayan M, Mozes E. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc Natl Acad Sci USA 1997 94 : 4620 5.
3. Waisman A, Shoenfeld Y, Blank M, Ruiz PJ, Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Imuunol 1995 7 : 689 96.
4. Luger D, Dayan M, Zinger H, Liu JP, Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004 24 : 579 90.
5. Eilat E, Zinger H, Nyska A, Mozes E. Prevention of lupus-erythematosus- like disease in (NZB×NZW) F1 mice by treating with CDR1 and CDR3-based peptides of a pathogenic autoantibody. J Clin Immunol 2000 20 : 268 78.
6. Eilat E, Dayan M, Zinger H, Mozes E. The mechanism by which a peptide based on the complementarity determining region-1 of a pathogenic anti-DNA autoantibody ameliorates experimental SLE. Proc Natl Acad Sci USA 2001 98 : 1148 53.
7. Zinger H, Eilat E, Meshorer A, Mozes E. Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZB×NZW) F1 mice via active suppression. Intern Immunol 2003 15 : 205 14.
8. Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E. A peptide based on the complementarity determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-β. Proc Natl Acad Sci USA 2006 103 : 8810 5.
9. Sharabi A, Haviv A, Zinger H, Dayan M, Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone. different effects on cytokines and apoptosis. Clin Immunol 2006 119 : 146 55.
10. Sela U, Hershkoviz R, Cahalon L, Lider O, Mozes E. Down-regulation of stromal cell-derived factor-1alpha-induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGF-beta secretion. J Immunol 2005 174 : 302 9.
11. Sela U, Mauermann N, Hershkoviz R, et al. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-beta-mediated suppression of LFA-1 and CD44 expression and function. J Immunol 2005 175 : 7255 63.
12. Takeno M, Suzuki N, Nagafuchi H, Mizushima Y, Sakane T. Selective suppression of resting B cell function in patients with systemic lupus erythematosus treated with cyclophosphamide. Clin Exp Rheumatol 1993 11 : 263 70.
13. Ozer H, Cowens JW, Colvin M, Nussbaum-Blumenson A, Sheedy D. In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration. J Exp Med 1982 155 : 276 90.
14. Waer M, Van Damme B, Leenaerts P, Roles L, van der Schueren E, Vandeputte M, Michielsen P. Treatment of murine lupus nephritis with cyclophosphamide or total lymphoid irradiation. Kidney Int 1988 34 : 678 82.
15. Cavallo T, Graves K, Granholm NA. Murine lupus nephritis: effects of cyclophosphamide on circulating and tissue bound immunoreactants. Clin Exp Immunol 1984 55 : 67 73.
16. Tsokos GC, Nambiar MP, Tenbrock K, Juang YT. Rewiring the T-cell. Signalling defects and novel prospects for the treatment of SLE. Trend Immunol 2003 24 : 259 63.
17. Ito S, Ueno M, Nishi S, Arakawa M, Fujiwara M. Suppression of spontaneous murine lupus by inducing graft-versus-host reaction with CD8+ cells. Clin Exp Immunol 1992 90 : 260 5.
18. Filaci G, Bacilieri S, Fravega M, et al. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 2001 166 : 6452 7.
19. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000 101 : 455 8.
20. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol 2000 18 : 423 49.
21. La Cava A, Ebling FM, Hahn BH. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand black × New Zealand White) F1 mice suppress in vitro production of antibodies to DNA. J Immunol 2004 173 : 3542 8.
22. Kang HK, Michaels MA, Berner BR, Datta SK. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 2005 174 : 3247 55.
23. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001 166 : 2913 16.
24. Schiffer L, Sinha J, Wang X, et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003 171 : 489 97.
25. Cunnane G, Chan OTM, Cassafer G, Brindis S, Kaufman E, Benedict Yen TS, Daikh DI. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum 2004 50 : 1539 48.